S-1/A: Windtree Therapeutics Files S-1/A for Resale of Over 62 Million Shares Amidst Going Concern Doubts

Windtree Therapeutics, a biotechnology company, has filed an S-1/A registration statement to allow selling stockholders to resell up to 62.6 million shares of common stock, with the company not receiving any proceeds from these sales, while facing substantial doubt about its ability to continue as a going concern.

Summary

• Windtree Therapeutics is registering up to 62,600,618 shares of common stock for resale by existing selling stockholders, including shares from Series D convertible preferred stock, Senior Secured Promissory Notes, and warrants.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders.
• Windtree Therapeutics is a biotechnology company focused on advancing therapies for critical conditions, with a portfolio including istaroxime for acute heart failure and cardiogenic shock, preclinical SERCA2a activators, rostafuroxin for hypertension, and a preclinical aPKCi inhibitor for oncology.
• A new corporate strategy was launched in January 2025 to become a revenue-generating biotech company through acquisitions of small companies with FDA-approved products, planning to use equity for these acquisitions.
• The company has incurred significant operating losses, with $26.1 million in 2024 and $20.6 million in 2023, and an accumulated deficit of $846.6 million as of December 31, 2024.
• Cash and cash equivalents were $1.8 million as of December 31, 2024, and $1.2 million as of March 31, 2025, with current liabilities of $5.7 million and $6.5 million, respectively.
• Auditors' opinion on the December 31, 2024 financial statements includes an explanatory paragraph stating substantial doubt about the company's ability to continue as a going concern.
• Recent capital raises include approximately $2.5 million from Series D Preferred Stock in April 2025, and an aggregate of $4.303 million from various convertible promissory notes and warrants issued between June 5, 2025, and July 2, 2025.
• The company made a one-time payment of $600,000 on May 2, 2025, to retire $625,000 in March and April Notes at a discount.

Sentiment

Score: 2

Explanation: The document highlights severe financial distress, including significant operating losses, a large accumulated deficit, and an explicit 'going concern' warning from auditors. While the company is pursuing new strategies and has ongoing clinical trials, its immediate financial viability is highly uncertain, and the current filing does not provide direct capital to the company. The positive clinical updates are overshadowed by the critical financial situation.

Positives

• Istaroxime, a lead product candidate, has Fast Track designation from the U.S. FDA for acute heart failure.
• Positive topline results were announced in September 2024 from the Phase 2b SEISMiC Extension Study for istaroxime, showing significant improvement in cardiac function and blood pressure without increasing heart rate or clinically significant cardiac rhythm disturbances.
• Initiated a study in more severe SCAI Stage C cardiogenic shock (SEISMiC C Study) to evaluate istaroxime's safety and efficacy.
• Launched a new corporate strategy in January 2025 to become a revenue-generating biotech company through acquisitions of small companies with FDA-approved products, leveraging management's commercialization expertise.
• Acquired assets of Varian Biopharmaceuticals, Inc. in April 2024, including a novel aPKCi inhibitor with potential broad oncology applications.

Negatives

• Incurred significant operating losses of $26.1 million for the year ended December 31, 2024, and $20.6 million for 2023.
• Reported an accumulated deficit of $846.6 million as of December 31, 2024.
• Cash and cash equivalents were critically low at $1.8 million as of December 31, 2024, and further decreased to $1.2 million as of March 31, 2025.
• Auditors' opinion includes an explanatory paragraph stating substantial doubt about the company's ability to continue as a going concern.
• Current resources are believed to fund operations only through July 2025, necessitating additional capital.
• The company will not receive any proceeds from the current offering of 62.6 million shares, as it is a resale by selling stockholders.
• The sale of a substantial number of shares by selling stockholders could cause the common stock price to decline and make it harder for the company to raise future equity.

Risks

• Substantial doubt exists about the ability to continue as a going concern due to recurring losses and negative cash flows.
• Ability to advance development programs is dependent on securing additional capital through public/private securities offerings, convertible debt, strategic opportunities, or grants, with no assurance of success.
• Failure to obtain additional financing could force the company to limit or cease development activities and operations, materially adversely affecting the business.
• Future equity offerings and other issuances of securities could lead to significant dilution for existing stockholders.
• The sale of a large number of shares by selling stockholders could depress the market price of common stock.
• Restrictive covenants from prior PIPE Purchase Agreements may make it difficult to procure additional financing.
• Expectation to continue incurring significant operating losses for the foreseeable future, with no guarantee of achieving or sustaining profitability.
• Potential delays and uncertainties in anticipated timelines and milestones due to geopolitical events (Israel-Gaza, Russia-Ukraine, US-China tensions) affecting clinical trial operations.
• Difficulties and expenses associated with obtaining and maintaining regulatory approval for product candidates.
• Risks related to manufacturing active pharmaceutical ingredients, drug product, and other necessary materials.
• Reliance on third parties (CROs, CMOs, contract laboratories) for critical operations.
• Competition from existing and future therapies and products.
• Exposure to product liability lawsuits.
• Ability to obtain and maintain intellectual property protection for product candidates.
• Impact of recently enacted and future healthcare legislation, such as the Inflation Reduction Act of 2022.
• Ability to recruit or retain key scientific, commercial, or management personnel.
• Cybersecurity risks, including securing electronically stored work product and preventing cyber-attacks.
• Economic uncertainty from inflation and interest rate fluctuations, and concerns about financial institution liquidity.
• Challenges in successfully implementing the new business strategy to generate revenue through acquisitions of small companies with FDA-approved products.

Future Outlook

Windtree Therapeutics expects to continue incurring significant research and clinical development, regulatory, and other expenses as it develops product candidates, seeks regulatory approvals, conducts clinical trials, and prepares for manufacturing, marketing, and sales. The ability to advance development programs is dependent on securing additional capital through various financing efforts or business development activities. The company plans to pursue non-dilutive sources of capital as well as potential private and public securities offerings. The SEISMiC C Study for cardiogenic shock is expected to complete enrollment in Q1 2026, with an unblinded data review planned for Q3 2025. The new corporate strategy aims to generate revenue through acquisitions of small companies with FDA-approved products, with the number of deals depending on valuation and growth potential.

Management Comments

• Jed Latkin is the President and Chief Executive Officer of Windtree Therapeutics, Inc.

Industry Context

Windtree Therapeutics operates in the highly capital-intensive biotechnology sector, focusing on critical conditions like heart failure and oncology. The company's new strategy to acquire small companies with FDA-approved products reflects a broader industry trend where smaller biotechs, often struggling with commercialization, become targets for companies seeking to establish revenue streams. This strategy aims to leverage management's commercialization expertise across multiple therapeutic areas, potentially creating synergies. The reliance on external financing, particularly through convertible notes and preferred stock, is common for development-stage biotech companies, but the explicit 'going concern' warning highlights significant financial challenges that are more severe than typical for the industry.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• WINT Real Estate, LLC, a wholly owned subsidiary of the Company, entered into an Assignment and Conditional Assumption Agreement with Way Maker Growth Fund, LLC relating to the acquisition of the Aubrey Property.
• The company entered into various note purchase agreements with institutional investors (DFU, LLC, Keystone Capital Partners, LLC, Seven Knots, LLC, C/M Capital Master Fund LP, WVP Emerging Manager Onshore Fund, Frank Celli) for convertible promissory notes and warrants. Some of these entities (Seven Knots, Keystone) have had prior material relationships, including equity line agreements and previous note purchases.

Stakeholder Impact

• Shareholders: Face significant potential dilution from the conversion of preferred stock, notes, and warrants, as well as future capital raises. The current offering is a resale, meaning no direct capital infusion to the company, which could depress share price. The 'going concern' warning indicates high investment risk.
• Employees: The company's ability to continue operations and development activities is dependent on securing additional capital, which directly impacts job security and the continuity of research programs.
• Customers (potential): The development of product candidates like istaroxime for critical conditions could offer new treatment options, but the company's financial instability poses a risk to the successful completion and commercialization of these therapies.
• Suppliers/Creditors: The company's precarious financial position and 'going concern' doubt raise concerns about its ability to meet contractual obligations and make timely payments.
• Regulatory Authorities: The company's ongoing clinical trials and efforts to secure regulatory approvals are subject to the company's financial stability and ability to fund these activities.

Next Steps

• Seek stockholder approval for the issuance of common stock upon conversion of Series D Preferred Shares in accordance with Nasdaq rules.
• File a registration statement with the SEC covering the resale of Registrable Securities on or before the 15th calendar day following the closing of the Private Placement.
• Cause the registration statement to be declared effective by the SEC on or before the 45th calendar day following the Closing Date.
• Complete enrollment for the SEISMiC C Study in Q1 2026.
• Conduct an unblinded review of data from the first 20 subjects in the SEISMiC C Study in Q3 2025.
• Secure adequate resourcing for the SEISMiC C Study through financing efforts or business development activities.
• Advance investigational new drug (IND) enabling activities for the aPKCi inhibitor platform and determine the expected clinical development plan.
• Pursue potential licensing arrangements and/or other strategic partnerships for rostafuroxin.
• Continue to pursue non-dilutive sources of capital as well as potential private and public securities offerings.
• Seek acquisition targets to achieve the new corporate strategy of acquiring small companies with FDA-approved products.
• WINT LLC to meet Assumption Conditions for the Aubrey Property acquisition, including amending the Aubrey Purchase Agreement, reviewing and approving the Development Agreement, title commitment, survey, and contracts.
• Potentially extend the Aubrey Closing Date by up to two times, each for 30 days, by paying $1,000,000 per extension.

Key Dates

Recommendation

Keywords

Biotechnology, SEC Filing, S-1/A, Common Stock Resale, Going Concern, Capital Raise, Istaroxime, Cardiogenic Shock, Acute Heart Failure, Oncology, SERCA2a Activators, Rostafuroxin, Clinical Trials, Drug Development, Nasdaq Capital Market, WINT, Dilution, Private Placement, Convertible Notes, Warrants, Corporate Strategy, Acquisitions